有効性評価に基づく前立腺がん検診ガイドライン

 
添付書類2

添付書類2:最終追加文献リスト 委員会20文献(AF1)+USPSTF5文献(治療不利益)+久道班1文献+外部評価委員9文献=35文献
ガイドライン引用No 追加要因 Auther Title Journal Volumes Issue Pages Year
24 委員会 Friedman GD, Hiatt RA, Quesenberry CP Jr, Selby JV. Case-control study of screening for prostatic cancer by digital rectal examinations. Lancet 337   1526-9 1991
25 委員会 Richert-Boe KE, Humphrey LL, Glass AG, Weiss NS. Screening digital rectal examination and prostate cancer mortality: a case-control study. J Med Screen 5 2 99-103 1998
27 委員会 Jacobsen SJ, Bergstralh EJ, Katusic SK, Guess HA, Darby CH, Silverstein MD, Oesterling JE, Lieber MM. Screening digital rectal examination and prostate cancer mortality: a population-based case-control study. Urology 52 2 173-9 1998
32 委員会(コクランSR引用文献) Sandblom G, Varenhorst E, Löfman O, Rosell J, Carlsson P. Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden. Eur Urol 46   717-24 2004
33 委員会 Aus G, Bergdahl S, Lodding P, Lilja H, Hugosson J. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer--results from a prospective, population-based randomized controlled trial. Eur Urol 51 3 659-64 2007
37 委員会 Concato J, Wells CK, Horwitz RI, Penson D, Fincke G, Berlowitz DR, Froehlich G, Blake D, Vickers MA, Gehr GA, Raheb NH, Sullivan G, Peduzzi P. The effectiveness of screening for prostate cancer: a nested case-control study. Arch Intern Med 166   38-43 2006
38 委員会 Kopec JA, Goel V, Bunting PS, Neuman J, Sayre EC, Warde P, Levers P, Fleshner N. Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case-control study. J Urol 174   495-9 2005
41 委員会 Coldman AJ, Phillips N, Pickles TA. Trends in prostate cancer incidence and mortality: an analysis of mortality change by screening intensity. CMAJ 168 1 31-5 2003
43 委員会 Threlfall TJ, English DR, Rouse IL. Prostate cancer in Western Australia: trends in incidence and mortality from 1985 to 1996. Med J Aust 169   21-4 1998
44 委員会 Skarsgard D, Tonita J. Prostate cancer in Saskatchewan Canada, before and during the PSA era. Cancer Causes Control 11   79-88 2000
45 委員会 Majeed A, Babb P, Jones J, Quinn M. Trends in prostate cancer incidence, mortality and survival in England and Wales 1971-1998. BJU Int 85   1058-62 2000
46 委員会 Post PN, Kil PJ, Crommelin MA, Schapers RF, Coebergh JW. Trends in incidence and mortality rates for prostate cancer before and after prostate-specific antigen introduction. A registry-based study in southeastern Netherlands, 1971-1995. Eur J Cancer 34 5 705-9 1998
47 委員会 Brewster DH, Fraser LA, Harris V, Black RJ. Rising incidence of prostate cancer in Scotland: increased risk or increased detection? BJU Int 85   463-73 2000
48 委員会 Roberts RO, Bergstralh EJ, Katusic SK, Lieber MM, Jacobsen SJ. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota. J Urol 161   529-33 1999
50 委員会 Jemal A, Ward E, Wu X, Martin HJ, McLaughlin CC, Thun MJ. Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States. Cancer Epidemiol Biomarkers Prev 14 3 590-5 2005
51 委員会 Baade PD, Coory MD, Aitken JF. International trends in prostate-cancer mortality: the decrease is continuing and spreading. Cancer Causes Control 15   237-41 2004
66 久31 Kubota Y, Ito K, Imai K, Yamanaka H. Effectiveness of mass screening for the prognosis of prostate cancer patients in Japanese communities. Prostate 50 4 262-9 2002
76 外部評価委員 Kapoor DA, Klimberg IW, Malek GH, Wegenke JD, Cox CE, Patterson AL, Graham E, Echols RM, Whalen E, Kowalsky SF. Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy. Urology 52 4 552-8 1998
77 外部評価委員 Cooner WH, Mosley BR, Rutherford CL Jr, Beard JH, Pond HS, Terry WJ, Igel TC, Kidd DD. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. 1990. J Urol 167 2 Pt 2 966-75 2002
78 外部評価委員 Rodríguez LV, Terris MK. Risks and complications of transrectal ultrasound guided prostate needle biopsy: a prospective study and review of the literature. J Urol 160 6 Pt 1 2115-20 1998
79 外部評価委員 Djavan B, Waldert M, Zlotta A, Dobronski P, Seitz C, Remzi M, Borkowski A, Schulman C, Marberger M. Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. J Urol 166 3 856-60 2001
81 外部評価委員 Crawford ED, Haynes AL Jr, Story MW, Borden TA. Prevention of urinary tract infection and sepsis following transrectal prostatic biopsy. J Urol 127 3 449-51 1982
82 外部評価委員 Aron M, Rajeev TP, Gupta NP. Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. BJU Int 85 6 682-5 2000
83 外部評価委員 Norberg M, Holmberg L, Häggman M, Magnusson A. Determinants of complications after multiple transrectal core biopsies of the prostate. Eur Radiol 6 4 457-61 1996
84 外部評価委員 熊谷章,小川大輔,小山敏樹,竹内一郎,大山格. 経直腸的前立腺生検後にフルニエ壊疽を発症した管理不良な糖尿病患者の1例. 日本泌尿器科学会雑誌 93 5 648-51 2002
85 外部評価委員 長谷川太郎,下村達也,山田裕紀,伊藤博之,加藤伸樹,長谷川倫男,浅野晃司,清田浩,池本庸,小野寺昭一,大石幸彦. 経直腸的前立腺針生検による敗血症性ショックの1死亡例. 感染症学雑誌 76 10 893-7 2002
86 USPSTF Stanford JL, Feng Z, Hamilton AS, Gilliland FD, Stephenson RA, Eley JW, Albertsen PC, Harlan LC, Potosky AL. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 283 3 354-60 2000
87 委員会 Schover LR, Fouladi RT, Warneke CL, Neese L, Klein EA, Zippe C, Kupelian PA. The use of treatments for erectile dysfunction among survivors of prostate carcinoma. Cancer 95 11 2397-407 2002
88 USPSTF Lu-Yao GL, McLerran D, Wasson J, Wennberg JE. An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. JAMA 269 20 2633-6 1993
89 USPSTF Steineck G, Helgesen F, Adolfsson J, Dickman PW, Johansson JE, Norlén BJ, Holmberg L; Scandinavian Prostatic Cancer Group Study Number 4. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 347 11 790-6 2002
90 委員会 Potosky AL, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, Penson DF, Harlan LC. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 96 18 1358-67 2004
91 USPSTF Potosky AL, Legler J, Albertsen PC, Stanford JL, Gilliland FD, Hamilton AS, Eley JW, Stephenson RA, Harlan LC. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 92 19 1582-92 2000
93 USPSTF Talcott JA, Rieker P, Clark JA, Propert KJ, Weeks JC, Beard CJ, Wishnow KI, Kaplan I, Loughlin KR, Richie JP, Kantoff PW. Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. J Clin Oncol 16 1 275-83 1998
94 委員会 Arai Y, Egawa S, Tobisu K, Sagiyama K, Sumiyoshi Y, Hashine K, Kawakita M, Matsuda T, Matsumoto K, Fujimoto H, Okada T, Kakehi Y, Terachi T, Ogawa O. Radical retropubic prostatectomy: time trends, morbidity and mortality in Japan. BJU Int 85 3 287-94 2000
95 委員会 Hisasue S, Takahashi A, Kato R, Shimizu T, Masumori N, Itoh N, Tsukamoto T. Early and late complications of radical retropubic prostatectomy: experience in a single institution. Jpn J Clin Oncol 34 5 274-9 2004

 

 
ページトップへ

ガイドライン解説

close-ico
カテゴリで探す
五十音で探す

診療ガイドライン検索

close-ico
カテゴリで探す
五十音で探す